Overview
- Revolution Medicines said the Phase 3 RASolute 302 results for its pill daraxonrasib will be presented in an ASCO Plenary Session on May 31 in Chicago, with Dana‑Farber’s Brian M. Wolpin as presenter.
- Topline data showed daraxonrasib met all primary and key secondary endpoints and extended median overall survival to 13.2 months versus 6.7 months on chemotherapy, with a reported 60% lower risk of death.
- Daraxonrasib is an oral RAS(ON) inhibitor designed to block RAS signaling, a pathway active in more than 90% of pancreatic ductal adenocarcinomas.
- The FDA has granted Breakthrough Therapy and Orphan Drug designations and placed the program in a National Priority Voucher pilot intended to speed review.
- Clinicians are awaiting the ASCO readout for subgroup and safety details after reports of rashes, gastrointestinal issues, and a trial patient who experienced facial bleeding.